Website Search
ID 1014

Diagnosis, Targeted therapies: Targeting activators, Sawyer 2

Description:
Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.
Transcript:
Charles Sawyer, M.D. is professor of medicine and director of the Prostate Cancer Program Area at U.C.L.A. Johnsson Comprehensive Cancer Center, and an investigator of the Howard Hughes Medical Institute. He works on therapies that target specific mutations in prostate cancer and chronic myeloid leukemia (CML). Here he describes his work developing a targeted therapy for CML patients with resistance to the anti-cancer drug Gleevec. “So Gleevec is a pill taken once a day and it is, works remarkably well in all phases of CML. So at the beginning, it was tested in patients with CML who had it for many years and failed standard chemotherapy type treatments. It worked extremely well there, and now is used as front line therapy in essentially all patients with CML. It's taken once a day, there's very little in the way of side effects. Patients live essentially a normal life. If patients are in the later stages' of CML when they start Gleevec, it works quite well, but resistance develops generally after six months to a year. When patients who are newly diagnosed with CML start Gleevec, so far it appears to be working remarkably well for three to four years now of follow-up. That's the longest follow-up we have. But about 15% of patients have developed resistance in that early diagnosis group.”
Keywords:
chronic myeloid leukemia, prostate cancer program, hughes medical institute, cml patients, comprehensive cancer center, charles sawyer, gleevec, cancer drug, prostate cancer, howard hughes, mutations, chemotherapy, leukemia, diagnosis, resistance, medicine
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
1016. Diagnosis, Targeted therapies: Targeting activators, Sawyer 4
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.
1015. Diagnosis, Targeted therapies: Targeting activators, Sawyer 3
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
1012. Diagnosis, Targeted therapies: Targeting activators
In this section learn that tyrosine kinases are a family of activator proteins that trigger the cell signaling process leading to cell growth and division.
1010. Diagnosis, Targeted therapies
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving